340 related articles for article (PubMed ID: 22882073)
21. Emerging Therapeutic Strategies for Overcoming Proteasome Inhibitor Resistance.
Dolloff NG
Adv Cancer Res; 2015; 127():191-226. PubMed ID: 26093901
[TBL] [Abstract][Full Text] [Related]
22. [Histone deacetylase inhibitors: new synergistic third-line option in multiple myeloma].
Stegmann DA
Med Monatsschr Pharm; 2016 Apr; 39(4):142-7. PubMed ID: 27209894
[TBL] [Abstract][Full Text] [Related]
23. Oxidative stress and proteasome inhibitors in multiple myeloma.
Lipchick BC; Fink EE; Nikiforov MA
Pharmacol Res; 2016 Mar; 105():210-5. PubMed ID: 26827824
[TBL] [Abstract][Full Text] [Related]
24. Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities.
Shay G; Hazlehurst L; Lynch CC
J Mol Med (Berl); 2016 Jan; 94(1):21-35. PubMed ID: 26423531
[TBL] [Abstract][Full Text] [Related]
25. Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma.
Jagannath S; Dimopoulos MA; Lonial S
Leuk Res; 2010 Sep; 34(9):1111-8. PubMed ID: 20472288
[TBL] [Abstract][Full Text] [Related]
26. Salvage therapy of multiple myeloma: the new generation drugs.
Romano A; Conticello C; Cavalli M; Vetro C; Di Raimondo C; Di Martina V; Schinocca E; La Fauci A; Parrinello NL; Chiarenza A; Di Raimondo F
Biomed Res Int; 2014; 2014():456037. PubMed ID: 24967371
[TBL] [Abstract][Full Text] [Related]
27. PI3K/AKT/mTOR pathway in multiple myeloma: from basic biology to clinical promise.
Ramakrishnan V; Kumar S
Leuk Lymphoma; 2018 Nov; 59(11):2524-2534. PubMed ID: 29322846
[TBL] [Abstract][Full Text] [Related]
28. Current advances in non-proteasome inhibitor-based approaches to the treatment of relapsed/refractory multiple myeloma.
Singla A; Kumar S
Oncology (Williston Park); 2011 Nov; 25 Suppl 2():32-43. PubMed ID: 25188483
[TBL] [Abstract][Full Text] [Related]
29. Proteasome inhibition in multiple myeloma: lessons for other cancers.
Saavedra-GarcĂa P; Martini F; Auner HW
Am J Physiol Cell Physiol; 2020 Mar; 318(3):C451-C462. PubMed ID: 31875696
[TBL] [Abstract][Full Text] [Related]
30. The Role of Intracellular Signaling Pathways in the Pathogenesis of Multiple Myeloma and Novel Therapeutic Approaches.
Kizaki M; Tabayashi T
J Clin Exp Hematop; 2016; 56(1):20-7. PubMed ID: 27334854
[TBL] [Abstract][Full Text] [Related]
31. [Multiple myeloma : What has been confirmed in therapy?].
Baertsch MA; Goldschmidt H
Internist (Berl); 2017 Dec; 58(12):1250-1257. PubMed ID: 29098319
[TBL] [Abstract][Full Text] [Related]
32. Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma.
Lonial S; Kaufman J; Reece D; Mateos MV; Laubach J; Richardson P
Expert Opin Biol Ther; 2016 Oct; 16(10):1291-301. PubMed ID: 27533882
[TBL] [Abstract][Full Text] [Related]
33. Role of carfilzomib in the treatment of multiple myeloma.
Khan RZ; Badros A
Expert Rev Hematol; 2012 Aug; 5(4):361-72. PubMed ID: 22992230
[TBL] [Abstract][Full Text] [Related]
34. New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings.
Ocio EM; Mateos MV; Maiso P; Pandiella A; San-Miguel JF
Lancet Oncol; 2008 Dec; 9(12):1157-65. PubMed ID: 19038762
[TBL] [Abstract][Full Text] [Related]
35. New Drugs in Multiple Myeloma.
Kunacheewa C; Orlowski RZ
Annu Rev Med; 2019 Jan; 70():521-547. PubMed ID: 30691369
[TBL] [Abstract][Full Text] [Related]
36. Proteasome inhibitors for multiple myeloma.
Okazuka K; Ishida T
Jpn J Clin Oncol; 2018 Sep; 48(9):785-793. PubMed ID: 30102324
[TBL] [Abstract][Full Text] [Related]
37. [Drug-Resistant Mechanism of Multiple Myeloma and Its Therapy Combined with HDACi -Review].
Gu LF; Cui XG; Cao XM; Chen SP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):608-612. PubMed ID: 28446321
[TBL] [Abstract][Full Text] [Related]
38. Developing novel strategies to target B-cell malignancies.
Fowler N; Oki Y
Am Soc Clin Oncol Educ Book; 2013; ():366-72. PubMed ID: 23714549
[TBL] [Abstract][Full Text] [Related]
39. Novel therapeutic strategies for multiple myeloma.
Mimura N; Hideshima T; Anderson KC
Exp Hematol; 2015 Aug; 43(8):732-41. PubMed ID: 26118499
[TBL] [Abstract][Full Text] [Related]
40. Emerging therapies targeting the ubiquitin proteasome system in cancer.
Weathington NM; Mallampalli RK
J Clin Invest; 2014 Jan; 124(1):6-12. PubMed ID: 24382383
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]